Expression and role of EGFR, cyclin�D1 and KRAS in laryngocarcinoma tissues

Abstract

Epidermal growth factor receptor (EGFR), cyclin D1 and KRAS proto-oncogene, GTPase (KRAS) genes serve roles in the occurrence and development of tumors. The aim of the current study was to investigate the expression levels of EGFR, cyclin D1 and KRAS in laryngocarcinoma tissues and their association with clinical features. In addition, correlation between the expression levels of EGFR, cyclin D1 and KRAS was analyzed in laryngocarcinoma tissues. The expression levels of EGFR, cyclin D1 and KRAS in 46 patients with laryngocarcinoma and 20 patients with vocal cord polyps as the control group were determined using Super Vision immunohistochemical staining assay kits. The differences in clinical and pathological parameters between groups were statistically analyzed using SPSS software version 16.0. The expression rates of EGFR, cyclin D1 and KRAS were 71.7, 52.2 and 39.1%, respectively in laryngocarcinoma tissues, and 10.0, 5.0 and 10.0%, respectively in vocal cord polyps. There was a positive correlation between the expression levels of EGFR, cyclin D1 and KRAS. The expression of these genes was also closely associated with the clinical stage, treatment response and prognosis of patients with laryngocarcinoma. Multivariate analysis of prognosis using the Cox regression model indicated that EGFR expression in laryngocarcinoma tissues and the clinical stage of patients with laryngocarcinoma were closely associated with patient prognosis. The results of the current study indicated that EGFR, cyclin D1 and KRAS were synergistically involved in the occurrence and development of laryngocarcinoma, directly affecting the prognosis of patients. Additionally, high expression of EGFR, cyclin D1 and KRAS facilitated the invasion and metastasis of laryngocarcinoma cells. The expression of EGFR in laryngocarcinoma tissues and clinical stage were two independent risk factors affecting the prognosis of patients.

Evaluation of Cyclin D1 and Human Epidermal Growth Factor Receptor 2 Neu Protein Expression in Head and Neck Squamous Cell Carcinoma

“…A positive association was present with a decrease in overall survival and strong and moderate expression of cyclin D1, with a p-value of 0.002. A similar result was seen in a study conducted by Lin et al [ 17 ], where the authors stated that an increase in the expression score of cyclin D1 can be associated with poor overall survival. They further hypothesized that cyclin D1 expression influences the survival and prognosis of patients.…”

“…Moreover, the present study can suppose that cyclin D1 immunoexpression increases with an increase in the stage of the disease. Studies conducted by Zand et al [ 16 ], Lin et al [ 17 ], and Dhingra et al [ 14 ] showed similar results with a p-value of <0.05, thereby demonstrating a positive association between cyclin D1 expression and an increase in the grade of the tumor. On the contrary, the study conducted by Saawarn et al [ 18 ] did not show any association between an increase in stage and the expression of cyclin D1.…”

KRAS Protein Expression in Oral Squamous Cell Carcinoma: A Potential Marker for Progression and Prognosis

“…Four-μm thick re-cut was done from the paraffin blocks for each biopsy and stained with hematoxylin and eosin for routine histopathological examinations. The following histopathological features were evaluated: (a) confirmation of the diagnosis, (b) grading of squamous cell carcinoma according to the World Health Organization classification (4 th edition) (18), (c) assessment of the presence of lymph node metastases, perineural invasion (PNI), and lymphovascular invasion (LVI), and (d) pathologic staging according to American Joint Committee on Cancer (AJCC 8th edition) (19).…”

Occurrence of quadruple squamous cell carcinoma following allogeneic hematopoietic stem cell transplantation for leukemia: A case report

“…The MAPK pathway is known to be closely associated with malignant tumors of the epithelium, and EGFR, KRAS and BRAF genes are all major effector molecules of the pathway. In fact, upregulated expression levels of EGFR have been detected in numerous types of tumor tissues (39). In the present study, no mutations were identified in cell-free tumor cells of the peripheral blood, or within the EGFR, KRAS and BRAF genes in the tumor tissue following the operation; however, immunohistochemistry analysis revealed that the EGFR protein expression levels in the tumor tissues were upregulated, which may be related to the amplification of the EGFR gene or the dysregulation of the MAPK signaling pathway.…”